NCT04372277: A trial that was reported late by Psoriasis Treatment Center of Central New Jersey
This trial has reported, although it was 744 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT04372277 |
|---|---|
| Title | Open Label Study, Evaluating Taltz in Combination With Enstilar (Calcipotriene and Betamethasone Dipropionate) Foam in Psoriasis Patients |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | April 28, 2020 |
| Completion date | March 1, 2021 |
| Required reporting date | March 1, 2022, midnight |
| Actual reporting date | March 14, 2024 |
| Date last checked at ClinicalTrials.gov | Aug. 26, 2025 |
| Days late | 744 |